Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
21.57
-0.06 (-0.28%)
Aug 17, 2026, 3:29 PM EDT - Market open
Amylyx Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
136
Market Cap
2.40B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 87.37M | -293.42M | -77.06% |
| Dec 31, 2023 | 380.79M | 358.56M | 1,612.94% |
| Dec 31, 2022 | 22.23M | 21.95M | 7,700.00% |
| Dec 31, 2021 | 285.00K | -365.00K | -56.15% |
| Dec 31, 2020 | 650.00K | -776.00K | -54.42% |
| Dec 31, 2019 | 1.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.85B |
| Perrigo Company | 4.14B |
| Trulieve Cannabis | 1.14B |
| Prestige Consumer Healthcare | 1.10B |
| ANI Pharmaceuticals | 978.38M |
| BioCryst Pharmaceuticals | 940.61M |
| Supernus Pharmaceuticals | 830.44M |
| HUTCHMED (China) | 549.12M |
AMLX News
- 8 hours ago - Amylyx price target raised to $30 from $24 at Mizuho - TheFly
- 7 days ago - Amylyx price target raised to $30 from $22 at BofA - TheFly
- 10 days ago - Amylyx price target raised to $28 from $19 at Baird - TheFly
- 11 days ago - Amylyx Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 11 days ago - Amylyx Pharmaceuticals Earnings release: Q2 2026 - Filings
- 11 days ago - Amylyx Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 11 days ago - Amylyx sees cash runway into 2028 - TheFly
- 11 days ago - Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results - Business Wire